Abstract: A method of improving the health of hair emerging from a scalp comprising a reduction of oxidative stress in the scalp by application of a composition resulting in reduction in oxidative stress in pre-emergent hair as demonstrated by reduced oxidative stress in emergent hair.

Abstract: The present invention provides oral care compositions, and in particular toothpaste compositions comprising a calcium salt abrasive and a novel alginate-based binder and rheology modifier, together with methods of use and manufacture thereof.

Abstract: This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin D2 synthase level or activity; methods of stimulating hair growth, comprising the step of contacting a subject with a compound or composition capable of increasing or decreasing the activity or level of a target gene of the present invention, or with a protein product of the target gene or an analogue or mimetic thereof; and methods of testing for AGA and evaluating therapeutic methods thereof, comprising measuring PGD2 levels.

Abstract: The present invention provides resin beads that are capable of realizing a water repellent and oil repellent effect, and further, that are also capable of providing cosmetic materials excellent in persistence of makeup when added and used in cosmetic materials etc. because the resin beads themselves contain silicone in a fixed state, and the present invention also provides a process for producing the resin beads. Resin beads being resin particles (a copolymer) obtained by subjecting a monomer mixture containing a plurality of monomers each having a copolymerizable functional group to suspension polymerization in a state where at least a non-polymerizable silicone is present, the resin particles containing the silicon in a fixed state, and a process for producing the resin beads.

Abstract: A personal care cleansing composition comprising at least one copolymer X, wherein the copolymer X is synthesized from at least one monomer (A) being acrylamidopropyl-2-methyl-2-sulfonic acid or a salt thereof, at least one monomer (B) conforming to formula (I) wherein R5 is methyl or hydrogen, R3 and R4 are hydrogen, Y is oxygen, EO is an ethylene oxide unit, v is an integer from 7 to 25, R6 is an alkyl group having from 10 to 22 carbon atoms; and at least one crosslinker (D) conforming to formula (II) wherein n is an integer from 8 to 15; and wherein the personal care cleansing composition has a pH less than about pH 6.0 and a viscosity of greater than about 1200 cP at 20 rpm.

Abstract: Described are multi-component products and multi-step regimens for improving the look and/or feel of human skin. The products comprise a first composition comprising a humectant, a second composition comprising a non-volatile oil, and a third composition comprising substantially spherical particles. The regimens comprise the steps of: applying to the skin a first layer formed using a first composition comprising a humectant, followed by applying a second layer formed using a second composition comprising at least one non-volatile oil, followed by applying a third layer formed using a third composition comprising substantially spherical particles.

Abstract: The present invention relates to the use of polymer particles in the form of spherical micelles constituted of block copolymers, as additives for aqueous or organic solutions. More particularly, the invention relates to the use of said spherical polymer particles for improving the ageing resistance of an aqueous or organic composition.

Abstract: Compositions and methods of using them for protecting skin, hair and nails against exposure to high energy visible light are described. The compositions can include one or more natural oils or extracts which are effective to absorb the high energy visible light at least to some degree.

Abstract: A skin care composition for topical use wherein the composition comprises avocado & coconut cream oil, cucumber extract and dandelion root's extract and a method to prepare the composition comprising mixing coconut cream and avocado fruit to make a paste, followed by heating to remove moisture and then extract oil. Mixing the oil obtained with cucumber extract and dandelion extract. The composition is used as anti-aging and moisturizing composition and suitable to all skin types.

Abstract: This invention is a method of eliminating the number of microorganisms on the surface of skin, hair or nails, by contacting these surfaces with a water stable, antimicrobial silanol quaternary ammonium compounds (SQACs) and the trisilanol, polysiloxanol and water soluble polysiloxane derivatives thereof. The stabilizing agent is selected from a list of volatile, antimicrobial, naturally occurring, renewable phytochemical essential oils and extracts that easily form crystal clear microemulsions when water is added to the concentrated SQAC/essential oil mixture. These non-foaming oil in water microemulsions have excellent long term storage stability, are freeze/thaw stable, remain very low in viscosity and do not phase separate or precipitate for many months.

Abstract: A Borojo skin care product and a preparation method thereof are disclosed. The skin care product comprises a matrix and Borojo powder, and the preparation method thereof comprises the steps: mixing and homogeneously stirring the Borojo powder in the matrix to obtain the Borojo skin care product.

Abstract: A personal care composition includes an ozone-stressed yeast lysate; and a preservative, in which the preservative is selected from phenoxyethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, butylene glycol, pentylene glycol, methylparaben, propylparaben, butylparaben, benzalkonium chloride, Quaternium 15, methylisothiazolinone, methylchloroisothiazolinone, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, butylated hydroxytoluene, tocopherol, triclosan, chlorohexidine digluconate, and combinations thereof, and the ozone-stressed yeast lysate is produced by a method including exposing growing yeast to ozone by aerating the yeast for a time period of between five minutes and seventy-two hours with an aeration gas having an ozone concentration of from 0.0001 millimolar (mM) to 1.

Abstract: A method (and the resulting product) of making a medical implant device for releasing self-contained drugs on a controlled basis wherein the method utilizes, at least in part, computer-controlled 3-D printing equipment to deposit via nozzles portions of one or more layers of the medical implant product. The implant has an outer impervious coating, an inner matrix core, an opening and an optional bonding layer.

Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.

Abstract: The present disclosure is directed to disintegration systems for solid pharmaceutical dosage forms, which allow rapid disintegration of solid dosage forms that comprise solid dispersion formulations that include pharmaceutically active agents, polymers and optionally surfactants. The present disclosure is also directed to solid pharmaceutical dosage forms, such as tablets, comprising solid dispersion formulations and the disintegration systems, to methods for preparing the disintegration systems, and to methods for preparing the solid pharmaceutical dosage forms.

Abstract: Provided is an orally disintegrating tablet coated with film that allows the time elapsed before a film thereof dissolves to be shorter, has a good feel when the tablet is taken, and is capable of being easily mass-produced. The orally disintegrating tablet coated with film is coated with a film coating composition, the film coating composition comprises a water-soluble and ethanol-insoluble film coating base; and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol in a liquid or semisolid state at room temperature.

Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.

Abstract: The present disclosure relates to a method for the preparation of a nanosuspension of at least one natural material, wherein the method comprises the steps of (a) providing at least one natural material having a particle size (D90) of less than 320 ?m; (b) dispersing said at least one natural material of step (a) in a solvent; and (c) milling the dispersion of step (b) to a particle size (D90) of below 1000 nm. The nanosuspension is useful for the preparation of a medicament.

Abstract: The invention relates to a stable water-in-oil emulsion composition containing: 20% to 40% (v/v) aqueous phase in the form of droplets and containing an anti-cancer agent; and 60% to 80% (v/v) lipid phase containing an iodized oil and at least one surfactant, having Formula (I) as follows, in a proportion, of surfactant mass relative to the total volume of the composition, of 0.3% to 5%: wherein s is 0 or 1, m is a whole number from 2 to 30, R1 has Formula (II) as follows, and R2 and R3 are independently H or R1: wherein n is a whole number from 4 to 10, o is a whole number from 1 to 4, p is a whole number from 3 to 7, q is a whole number from 2 to 10, and r has a value of 0 or 1.

Abstract: The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.

Abstract: Nanoscale coordination polymer nanoparticles for the co-delivery of multiple therapeutic agents are described. The multiple therapeutic agents can include a combination of different chemotherapeutic agents, a combination of one or more chemotherapeutic agents and one or more nucleic acids, such as small interfering RNA (siRNA) or microRNA, a combination of one or more chemotherapeutic agents and a photosensitizer (i.e., for use in photodynamic therapy), or a plurality of different siRNAs. Pharmaceutical formulations including the nanoparticles, methods of using the nanoparticles to treat cancer, and methods of making the nanoparticles are also described.

Abstract: Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.

Abstract: A new scalable process to control the particle size and the particle size distribution, comprising5 steps: (i) suspension preparation in a mixture of solvents in which the API and/or excipient is partially soluble in one of the solvents; (ii) particle size reduction of the suspension; (iii) aging; (iv) stopping the aging by solvent removal; and (v) optionally, a step of isolating the processed ingredients in the form of powder.

Abstract: The present invention belongs to the field of pharmaceutical industry and relates to a solid pharmaceutical composition comprising androgen receptor antagonists, e.g. Enzalutamide or ARN-509, as well as to processes for preparing the same. The solid pharmaceutical compositions are useful in the treatment of prostate cancer.

Abstract: The preparation of dual functionalized nanoparticles is generally provided along with their application. The dual functionalized nanoparticles provide dual targeting and can effectively pass the blood brain barrier and target brain tissue. The dual targeted and dual responsive nanoparticles are functionalized to include at least two different ligands that are capable of transport across the blood brain barrier. The nanoparticles can be prepared from polymeric materials that can be biocompatible, provide long circulation life in a body, and be successfully ligated to both functionalities by use of acid-sensitive and/or redox potential-sensitive bonds for delivery across the blood brain barrier and delivery of a payload to brain tissue.

Abstract: The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g.

Abstract: A medical magnetic pellet is provided. The magnetic pellet includes a porous matrix and magnetic powder distributed in the porous matrix. Moreover, an active substance also can be added to be distributed in the matrix. The porous matrix of the magnetic pellet can carry active substances or absorb target substances.

Abstract: This invention discloses bioerodible delivery compositions for delivering peptide therapeutic agents. The delivery compositions comprise a porous silicon-based carrier material loaded with the therapeutic agent. The delivery compositions may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The delivery compositions may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Abstract: Provided are a solid composite formulation for oral administration, the solid composite formulation including: an ezetimibe granules-part including ezetimibe, said ezetimibe having a particle size distribution wherein the average particle size d(0.9) for the bottom 90% is about 10 ?m or less; and a rosuvastatin mixture-part including rosuvastatin or a pharmaceutically acceptable salt thereof, and a method of preparing the composite formulation.

Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “Ra” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Abstract: In one aspect, the present invention features a tablet including a compressed core and a liquid filled capsule, wherein the compressed core includes a first pharmaceutically active agent, the compressed core has a cavity exposed on the surface of the core, and the capsule is contained within the cavity such that a portion of the capsule is visible on the surface of the tablet, wherein the capsule has a diameter of at least 500 microns.

Abstract: Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages.

Abstract: One aspect of the invention is a polymer material comprising a capsule coated with PDA. In certain embodiments, the capsule encapsulates a functional agent. The encapsulated functional agent may be an indicating agent, healing agent, protecting agent, pharmaceutical drug, food additive, or a combination thereof.

Abstract: Disclosed is a method of preparing a hollow microcapsule using freezing of macroporous materials including a crosslinked inorganic particle network capable of elastically recovering from a highly compressed deformation state, and use of the same as a scaffold for soft tissue engineering and as a drug delivery system.

Abstract: Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.

Abstract: Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.

Abstract: Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.

Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.

Abstract: The present invention relates to a sealed package containing one wipe, wherein the one wipe comprises a carrier and an active ingredient impregnated therein, wherein the active ingredient is selected from the group consisting of penile desensitizing agents. The sealed package can be opened, the wipe removed and wiped on the penis of a male to reduce the occurrence of premature ejaculation during subsequent intercourse.

Abstract: The described invention provides a method for reducing visual loss and for treating one or more of adverse consequence of an eye disease, including abnormal intraocular pressure, retinal vascular disease, retinal ganglion cell death, or a combination thereof in order to reduce visual loss. The method entails providing a flowable particulate composition that contains a particulate formulation comprising a plurality of particles of uniform size distribution, a therapeutic amount of a therapeutic agent selected from a voltage-gated calcium channel antagonist, an endothelin receptor antagonist, or a combination thereof, and optionally an additional therapeutic agent, wherein the particles are of uniform size distribution, and wherein each particle comprises a matrix; and a pharmaceutically acceptable carrier.

Abstract: A combination of sheets can be combined into an ingestible unit. The individual sheets can be prepared to have one or more functionalities, such as providing a biologically active agent, disintegrating and opening the unit, controlling release of an agent, facilitating absorption from the GI tract, as well as many others. The individual sheets can be selectively identified for combining into a multifunctional ingestible unit with a random or predetermined arrangement or stacking pattern. The individual sheets can be loose in a capsule or laminated together into a stacked layered structure. The combination of sheets can be pressed, laminated, tableted, or otherwise prepared into an ingestible unit. The ingestible unit can be predetermined to be useful for administering a drug, drug combination, multi-drug regimen as well as tailored to subject-specific multi-drug therapeutic regimens. The sheets can be loaded with any type of agent ranging from drugs to anti-counterfeit agents.

Abstract: The present invention relates generally to the treatment of virus infections. More specifically, the present invention relates to compositions and methods to treat rotavirus infections.

Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.

Abstract: The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain.

Abstract: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.

Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.

Abstract: The present disclosure provides a compositions and methods of inhibiting 06-methylguanine DNA methyltransferase in human tumor cells by providing an effective amount of a disulfiram composition to inhibit the 06-methylguanine DNA methyltransferase in a pharmaceutically acceptable carrier to inhibit 06-methylguanine DNA methyltransferase.

Abstract: Methods of treating Prader-Willi syndrome in a subject in need of treatment are provided. The methods include administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R, R?, X, Y and Z are defined as set forth in the specification. In embodiments, an effective amount of captodiamine or a pharmaceutically acceptable salt thereof is administered to the subject.

Abstract: The present invention relates to extended release liquid compositions of guanfacine. The extended release liquid compositions of the present invention are bioequivalent to marketed extended release tablet compositions of guanfacine. Said extended release liquid compositions provide substantially similar in-vitro dissolution release profile upon storage for at least seven days. Further, the extended release liquid compositions are stable. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions.